Philip Band

As a researcher and professor of orthopaedic surgery, biochemistry, and molecular pharmacology at NYU School of Medicine, I am an expert in osteoarthritis, the extracellular matrix, hyaluronic acid, synovial fluid, and intra-articular injection therapies.

My work has spanned three related fields—medical applications of matrix polymers, orthopaedic medicine and injection devices, and recombinant botulinum neurotoxins. Dr. Joseph Zuckerman and I founded the Center for Clinical Research, where we began developing big data approaches to personalized musculoskeletal medicine.

I am the chief executive officer of CytoDel LLC, a biopharmaceutical company that was co-developed at NYU Langone. We have engineered recombinant derivatives of botulinum neurotoxin to create therapeutic fusion proteins designed to deliver single chain antibodies into neurons.

Throughout my career, I have been deeply involved in taking inventions from the laboratory and applying them to medical practice using preclinical testing, formulation, chemistry and manufacturing controls, clinical trial design, and regulatory compliance.